Masaya Kato

Masaya Kato

Auto-generated profile, based on publicly available information

Masaya Kato

Department of Pediatrics Dokkyo Medical University Tochigi Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MKMasaya Kato
Masaya Kato
MMManabu Miyamoto
Manabu Miyamoto
FTFumitaka Takayanagi
Fumitaka Takayanagi
YAYusuke Ando
Yusuke Ando
YFYuji Fujita
Yuji Fujita
SYShigemi Yoshihara
Shigemi Yoshihara
Pollen food allergy syndrome (PFAS) is caused by cross-reactivity with pollen; however, not all-pollen-sensitised individuals develop PFAS, and studies on the characteristics of PFAS development are limited in Japan. We investigated the prevalence and risk factors for the development of PFAS in Japanese children and adolescents sensitised to pollen and their association with pollen-specific IgE levels. The characteristics of PFAS were investigated in patients with allergies aged 3–18 years who visited Dokkyo Medical University Hospital between January 2016 and December 2019. Specific IgE levels for alder, Japanese cedar, ragweed, and orchard grass were measured in patients sensitised to any of the pollens. Patients were categorised into preschool (G1), elementary school (G2), and middle-high school (G3) groups. Overall, 600 patients were enrolled. The prevalence of PFAS was 8.5% in G1, 20% in G2, and 36.3% in G3. Multivariate logistic regression analysis demonstrated strong associations between the risk of developing PFAS and older age (odds ratio (OR), 1.12; 95% confidence interval (CI), 1.06–1.19; P < 0.001 ), seasonal allergy rhinitis (OR, 6.93; 95% CI, 1.59–30.34; P = 0.010 ), and alder sensitisation (OR, 6.20; 95% CI, 2.66–14.49; P < 0.001 ). Spearman’s correlation revealed statistically significant positive correlation between each pollen-specific IgE level; high pollen-specific IgE levels were also a risk factor. The OR for being sensitised to all four species was 36.83 (95% CI, 8.93–151.83, P < 0.001 ) when compared with Japanese cedar alone. Alder was most relevant, with an alder-specific IgE level cutoff value of 2.54 UA/mL. The sensitivity was 78.9%, and the specificity was 70.9%. In conclusion, preschool children develop PFAS with alder sensitisation, and higher pollen-specific IgE levels and increased number of pollen sensitisations are risk factors for developing PFAS.

10 June 2026 in Allergology International
Verified
Journal Article
Open access
SYShigemi Yoshihara
Shigemi Yoshihara
SYShinya Yoshihara
Shinya Yoshihara
MMManabu Miyamoto
Manabu Miyamoto
YFYuji Fujita
Yuji Fujita
MKMasaya Kato
Masaya Kato
HKHiroyuki Kitajima
Hiroyuki Kitajima
Delgocitinib ointment is a non-steroidal Janus kinase inhibitor approved for atopic dermatitis (AD). To address limitations of topical corticosteroids (TCS)-such as reduced adherence and efficacy due to the complexity of anatomical location-based potency adjustments, and patient reluctance to use high-ranked TCS-this study investigated the potential of combining delgocitinib ointment with a medium-ranked TCS (Japanese guideline) to induce remission in pediatric AD patients. Eligible Japanese AD patients aged 2 to under 16 years were randomized in a 1:1 ratio to receive either delgocitinib-TCS combination therapy or TCS monotherapy for 4 weeks in an open-label, parallel-group design. Assessments included Eczema Area and Severity Index (EASI), Numeric Rating Scale (NRS), Patient-Oriented Eczema Measure (POEM), and Validated Investigator's Global Assessment (vIGA) for efficacy, and adverse events (AEs) for safety. The study was registered with the Japan Registry of Clinical Trials (jRCTs031240119). Eighty-three and 84 pediatric AD patients received delgocitinib combination therapy and TCS monotherapy, respectively, and showed 71.74% and 60.03% reductions in EASI score after up to 4 weeks of treatment (primary endpoint). The delgocitinib combination group demonstrated a statistically significant 11.71% greater reduction compared to the TCS monotherapy group (p = 0.0383). The adverse drug reactions (ADRs) observed in the delgocitinib combination group were expected local events, and no notable safety concerns were identified with the addition of delgocitinib to TCS therapy. The combination of delgocitinib ointment and TCS is considered a promising novel therapeutic option for remission induction in pediatric patients with moderate to severe AD.

1 January 2000 in The Proceedings of The Manufacturing & Machine Tool Conference
Verified
Journal Article
Open access
PDF file
YWYongbo Wu
Yongbo Wu
MKM. Kato
M. Kato
KSK. Syoji
K. Syoji
TKT. Kuriyagawa
T. Kuriyagawa
TTT. Tachibana
T. Tachibana

8 December 2022
Verified
Preprint
Open access
PDF file
MKMasaya Kato
Masaya Kato
SYShigemi Yoshihara
Shigemi Yoshihara
Title: Sublingual-swallow immunotherapy was effective and safe in severe cow’s milk protein allergy: A pediatric case Author: Masaya kato, M.D.; Shigemi Yoshihara, M.D., Ph.DAffiliations: Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, JapanCorresponding author: Masaya KatoDepartment of Pediatrics, Dokkyo Medical University880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, JapanPhone: +81-282-87-2155, Fax: +81-282-86-7521E-mail: m-kato@dokkyomed.ac.jpWord, figure, and table count: 746 words, 1 figure.Financial support: This research received no external funding.Consent statement: Written informed consent was obtained from the patient’s parent and the patient for publication of this report and images.To the editor: Although an increasing number of patients with food allergy have been able to achieve tolerance and desensitization through oral immunotherapy, many children with severe Cow‘s milk (CM) allergy do not progress to oral immunotherapy and do not reach desensitization. We report a case in which sublingual-swallow immunotherapy was used to safely increase the dose of CM to 25 ml in a 12-year-old male patient who had a threshold of 1.2 ml of CM for induction of allergy symptoms.The patient had a history of five anaphylactic shocks since infancy after consuming less than 3 ml of CM, and had, therefore, eliminated CM completely from his diet. At age 11, the patient participated in a clinical study involving epicutaneous immunotherapy; however, that did not improve his symptom elicitation threshold. At age 12, casein-specific IgE 6.83 UA/ml, casein-specific IgG4 0.59 mgA/L and oral food challenge (OFC) of CM showed urticaria at 1.2 ml. Tingling of oral cavity was observed in OFC of 0.2 ml of CM, but no other symptoms were noted.We started sublingual-swallow immunotherapy, in which the patient held 0.2 ml of CM under his tongue for 2 minutes before consuming it orally, once a day. Initially, the patient complained of tingling in the oral cavity; however this disappeared within one week of therapy. The dose of CM was increased by 0.1 ml every week with no adverse events observed. As the amount increased, it could not be held only under the tongue, so it was held in the oral cavity. The dose was increased by 0.1 ml per day, 2 months after the start of therapy, but no allergic reaction was observed. After 3 months, the patient was able to consume 10 ml, and after 6 months, up to 30 ml of CM. Since he could not hold more than 20 ml, this amount was held in the oral cavity for 2 minutes before swallowing, while the rest was swallowed without holding. We performed OFC using a pancake containing 25 ml of CM, but no allergy-related symptoms were observed. Thereafter, at the patient’s request, he was given dairy products equivalent to 25 ml of milk 2–3 times a week. After a 2-week ban on CM at 14 months, an oral tolerance test (sweet bread equivalent to 25 ml of milk) was conducted, and the patient complained of mild oral discomfort, but consumed the entire amount without major symptoms. Casein-specific IgG4 levels increased, whereas casein-specific IgE levels decreased for the duration of this therapy. (Figure 1).Keet et al.1 reported that sublingual immunotherapy (SLIT) with CM was inferior to oral immunotherapy (OIT). However, the study compared three milk protein doses during the maintenance phase of immunotherapy: 7 mg in the SLIT group, 1 g in the OIT B group, and 2 g in the OIT A group, suggesting that increasing the SLIT dose may increase efficacy. A French pilot study reported that milk thresholds increased from an average of 39 ml (range 4–106 ml) to 143 ml (range 44–≥200 ml) after 6 months of treatment by holding milk under the tongue for 2 minutes and then spitting it out (starting at 0.1 ml and increasing to 1.0 ml).2 SLIT induces IL-10-producing regulatory T cells,3 promotes antigen-specific IgG4 production, and suppresses IgE production.4 In addition, since the oral mucosa is devoid of inflammatory cells, such as mast cells, basophils, and eosinophils, and rich in antigen-presenting cells, such as dendritic cells, SLIT induces immune tolerance with fewer adverse reactions.5During OFC and OIT for milk allergy, we experience that food such as pancakes require chewing, and are more successful than swallowing milk. This may lead to sublingual immune tolerance. In addition, holding the food in the oral cavity allows the patient to spit it out if symptoms are strong, which is safer than swallowing it. There have been reports of success with the combination of OIT and omalizumab,6.7 but not everyone can afford this treatment due to the high cost of medical care. In this respect, the present method is easy to perform because the dairy product is simply held in the oral cavity for two minutes and then swallowed. In this case, the patient’s oral tingling disappeared after one week of treatment, suggesting that the treatment induced immune tolerance by the sublingual mucosa, and we believe it is worthwhile to try it for severe CM allergy. We plan to perform this therapy on more cases and conduct a comparative study with OIT in future.

20 March 2023 in Indian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MKMasaya Kato
Masaya Kato
MMManabu Miyamoto
Manabu Miyamoto
YAYusuke Ando
Yusuke Ando
YFYuji Fujita
Yuji Fujita
SYShigemi Yoshihara
Shigemi Yoshihara

30 November 2025 in JEADV Clinical Practice
Verified
Journal Article
Open access
YFYuji Fujita
Yuji Fujita
SKSayuri Kajitani
Sayuri Kajitani
MMManabu Miyamoto
Manabu Miyamoto
YAYusuke Ando
Yusuke Ando
MKMasaya Kato
Masaya Kato
SYShigemi Yoshihara
Shigemi Yoshihara
Background: The Aiming High in Eczema/Atopic Dermatitis (AHEAD) approach, which combines treat‐to‐target principles and shared decision‐making, was proposed by international expert dermatologists. Objectives: To understand which atopic dermatitis (AD) features children with AD and their caregivers, who visited paediatric departments, consider important, we investigated which AD features patients/caregivers would choose as patient‐reported outcomes. Methods: The subjects were paediatric patients aged 0–18 years with AD. The patients and caregivers were asked to select one to three troublesome AD features as patient‐reported outcomes based on the AHEAD approach and rank them. For patients aged < 6 years, only their caregivers responded, whereas in the case of those aged ≥ 6 years, both the patients and their caregivers responded. Results: Overall, 290 patients were included, of whom 113 and 177 were aged < 6 and 6–18 years. The troublesome AD feature most commonly selected by caregivers of patients aged 0–5 years was itch (96/113, 85.0%), followed by skin appearance/condition (79/113, 69.9%) and sleep disturbance (43/113, 38.1%). The same features were most commonly selected by patients aged ≥ 6 years who answered their own questions, and the corresponding numbers were as follows: itch, 158/177 (89.3%); skin appearance/condition, 109/177 (61.6%); and sleep disturbance, 45/177 (25.4%). Furthermore, these AD features were compared in the 6–12 and 13–18 years groups ( n = 102 and 75, respectively). Skin appearance/condition was more commonly selected by the 13–18 years group compared with the 6–12 years group, and the intergroup difference was significant (13–18 years group: 86.7% vs. 6–12 years group: 44/102, 43.1%; p < 0.01). However, intergroup differences in other AD features were not significant. Conclusions: AD treatment aimed at true remission based on the AHEAD approach is desirable for children and their caregivers.